1 of 27

Methylation Episignature Testing: A diagnostic tool for VUS resolution and undiagnosed rare disease

Alexandra (Lexi) Hubbel, MS, CGC

Division of Clinical Genetics

NYSGTF Meeting 9/9/2026

Golisano Children’s

2 of 27

Conflicts of Interest

  • None
  • My experience with methylation episignature testing has been through EpiSign performed by Greenwood Genetics. I have no affiliation with this laboratory.

2

Golisano Children’s

3 of 27

Outline

  • Intro to methylation episignature testing
  • Who is this testing useful for?
  • Case examples

3

Golisano Children’s

4 of 27

DNA Methylation

  • At cytosine bases at CpG dinucleotides
  • Regulates gene expression
  • Methylation is mostly erased after zygote formation
  • Remethylation begins in the blastocyst stage

​

4

Golisano Children’s

5 of 27

The EpiGenome

  • Tissue specific – involved in cell differentiation
  • Changes over time
  • Lifestyle factors such as smoking, diet and infectious disease can alter the epigenome
  • Alterations can be seen in cancer – activation of growth-promoting genes

​

5

Golisano Children’s

6 of 27

What is methylation episignature testing?

  • Genome wide methylation array
    • Final result is a combination of 3 parameters
    • High confidence: all three agree
    • Moderate confidence: disagreement in at least one
  • Single gene variants in genes involved in the DNA methylation pathway can cause unique methylation differences across the genome – ‘epigenetic signature’
  • Comparison of patient’s DNA methylation to reference samples

​

6

Golisano Children’s

7 of 27

History of methylation episignature testing

  • EpiSign version 1 released in 2019 with analysis of 15 episignatures
    • Now on version 5 with over 100 conditions
  • Cincinnati Children’s has Episignature Analysis by Methylation Array

​

7

Kerkhof, 2024

Golisano Children’s

8 of 27

Approach to Genetic Testing for Rare Disease

8

Alegret-Garcia, 2025

Golisano Children’s

9 of 27

Diagnostic Utility of Methylation Episignature Testing

  • Publication of 2399 cases that underwent EpiSign testing (v1-3)
    • 1667 cases underwent comprehensive testing with a diagnostic yield of 18.7%
    • 732 cases underwent targeted analysis with a diagnostic yield of 32.4%

​

9

Kerkhof, 2024

Golisano Children’s

10 of 27

What conditions can be detected via methylation episignature testing?

  • Imprinting disorders (PWS, RSS, BWS, AS)
  • Trinucleotide repeats that cause methylation defects (Fragile X)
  • Many chromosomal conditions
  • Prenatal exposures
    • Fetal valproate (analysis available on request)
    • Fetal alcohol (not yet added to EpiSign)

10

Golisano Children’s

11 of 27

What conditions can be detected via methylation episignature testing?

  • Single gene conditions
    • Kabuki syndrome
    • CHARGE syndrome
    • Coffin Siris syndrome
    • Cornelia de Lange syndrome
    • Mowat Wilson
    • Sotos syndrome
    • Rubenstein Taybi syndrome
    • Pitt Hopkins syndrome
    • Koolen-De Vries syndrome
    • Wiedemann-Steiner syndrome

11

    • Kleefstra syndrome
    • White Sutton syndrome
    • Neuroocular syndrome
    • Wieacker-Wolff syndrome
    • Witteveen Kolk syndrome
    • Floating Harbor syndrome
    • Fanconi anemia (not all genes)
    • Chung-Jansen syndrome
    • Diets-Jongmans syndrome
    • PCR2 complex disorders (Weaver and Cohen-Gibson syndromes)
    • And MANY MORE!!!!

Golisano Children’s

12 of 27

What patients should get this testing?

  • Undiagnosed neurodevelopmental disorders
  • Identified VUS in gene with known epigenetic signature
  • Symptoms concerning for more than one imprinting disorder
  • Over or undergrowth conditions (RSS-like, BWS-like, etc)

12

Golisano Children’s

13 of 27

Case Examples – VUS resolution 1

  • Consulted on infant male in NICU with neonatal hypoglycemia and hyperinsulinemia
    • rWGS was ordered

​

13

Golisano Children’s

14 of 27

Case Examples – VUS resolution 1

14

  • By 1 year had global developmental delays and facial features consistent with Kabuki
  • Sibling also affected born 2 years later

Golisano Children’s

15 of 27

Case Examples – VUS resolution 2

  • Initially consulted for 4mo male admitted with failure to thrive, delays, hypotonia, bilateral 2-3 toe syndactyly, and hemangioma on his scalp
  • Born at 36 and 5/7, no NICU stay
  • Family history
    • Father with autism, LD, and history of speech delay
    • Mother with ADHD, auditory processing disorder, and a history of feeding difficulties in infancy (3 mo premature)
  • Sent CMA, deferred additional testing to outpatient setting

​

15

Golisano Children’s

16 of 27

Case Examples – VUS resolution 2

  • CMA resulted as negative
  • Seen for outpatient FUV at 8mo of age
    • Dysmorphic features noted including epicanthal folds, small upturned nose with long smooth philtrum, and inverted nipples
  • Proceeded with WES

16

Golisano Children’s

17 of 27

17

Golisano Children’s

18 of 27

Case Examples – VUS resolution 2

18

Golisano Children’s

19 of 27

Case Examples – Undiagnosed 1

  • Patient initially evaluated by genetics at 2 months of life for bilateral colobomas (involving the iris, optic nerve and choroid), and microphthalmia
  • Family returned to genetics clinic 10 years later after the patient’s brother was diagnosed with a de novo neurodevelopmental condition
    • Phenotype was updated to include autism and global developmental delays

​

19

Golisano Children’s

20 of 27

Case Examples – Undiagnosed 1

WGS in 2024 identified a VUS in DMD and low heteroplasmy VUS in RNR2

​

​

20

Golisano Children’s

21 of 27

Case Examples – Undiagnosed 1

  • White-Sutton syndrome
    • neurodevelopmental disorder cause by pathogenic variants in POGZ
    • Explains the patient’s neurodevelopmental presentation
  • Coffin-Siris syndrome 9
    • SOX11 gene plays a crucial role in embryonic eye development – associated with both coloboma and microphthalmia
  • Causative variants NOT identified on WGS

​

21

Golisano Children’s

22 of 27

Case Examples – Undiagnosed 2

  • 3yo male presented with FTT, global developmental delays, history of hypoglycemia in the NICU, and triangular face
    • High suspicion for RSS at this time (although more significant delays than typical with RSS)
    • Normal microarray
  • RSS testing (methylation and CNV of 11p15.5, UPD7, and CDKN1C sequencing) was negative
  • Whole exome sequencing was negative
  • Given clinical diagnosis of RSS
  • Whole genome sequencing was negative

​

22

Golisano Children’s

23 of 27

Case Examples – Undiagnosed 2

23

  • Caused by pathogenic variants in the SIN3A gene
  • Phenotype includes ID, small head, short stature, hypotonia. Seizures and behavioral concerns in a minority
  • Dysmorphism: tall broad forehead, down-slanting palpebral fissures, triangular face with pointed chin and thin upper lip
  • No causative variant identified on WGS

​

Golisano Children’s

24 of 27

Diagnostic Challenges

  • Moderate versus strong signatures
  • Genes with overlapping signatures
  • Unexpected findings
  • Inconclusive findings
  • Insurance coverage
  • Global hypomethylation is present in children under the age 1
  • Tissue specificity (blood)
  • Carrier detection, X-linked conditions in females

24

Golisano Children’s

25 of 27

Future of methylation epigenetic signature testing: Incorporation into long read sequencing?

25

Golisano Children’s

26 of 27

Thank you!

Golisano Children’s

27 of 27

References

  • Alegret-García, A., Cáceres, A., Sevilla-Porras, M., Pérez-Jurado, L.A., & González, J.R. (2025). Analysis Methods for Diagnosing Rare Neurodevelopmental Diseases with Episignatures: A Systematic Review of the Literature. Biomedicines, 13.
  • Balasubramanian, M., Dingemans, A.J.M., Albaba, S. et al. Comprehensive study of 28 individuals with SIN3A-related disorder underscoring the associated mild cognitive and distinctive facial phenotype. Eur J Hum Genet 29, 625–636 (2021). https://doi.org/10.1038/s41431-020-00769-7
  • Butler M. G. (2020). Imprinting disorders in humans: a review. Current opinion in pediatrics, 32(6), 719–729. https://doi.org/10.1097/MOP.0000000000000965
  • Ivashchenko, V., de Groot, M., Derks, R. et al. Genome-wide methylation detection and episignature analysis using PacBio long-read sequencing. Genome Med 18, 11 (2026). https://doi.org/10.1186/s13073-025-01506-9
  • Kerkhof, J., Rastin, C., Levy, M. A., Relator, R., McConkey, H., Demain, L., Dominguez-Garrido, E., Kaat, L. D., Houge, S. D., DuPont, B. R., Fee, T., Fletcher, R. S., Gokhale, D., Haukanes, B. I., Henneman, P., Hilton, S., Hilton, B. A., Jenkinson, S., Lee, J. A., Louie, R. J., … Sadikovic, B. (2024). Diagnostic utility and reporting recommendations for clinical DNA methylation episignature testing in genetically undiagnosed rare diseases. Genetics in medicine : official journal of the American College of Medical Genetics, 26(5), 101075. https://doi.org/10.1016/j.gim.2024.101075
  • https://ggc.org/tests/episign-complete/

​

27

Golisano Children’s